首页> 美国卫生研究院文献>Cancer Science >Multidrug Resistance Phenotype in the RMS‐GR Human Rhabdomyosarcoma Cell Line Obtained after Polychemotherapy
【2h】

Multidrug Resistance Phenotype in the RMS‐GR Human Rhabdomyosarcoma Cell Line Obtained after Polychemotherapy

机译:化疗后RMS‐GR人横纹肌肉瘤细胞系中的多药耐药表型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Classical cytotoxic treatment of rhabdomyosarcoma (RMS), the most common soft tissue malignancy in children, is often accompanied by significant morbidity and poor response. Chemotherapy may induce multidrug resistance (MDR) associated with the expression of P‐glycoprotein, a drug efflux pump which modifies the sensitivity of tumoral cells to drugs. To analyze MDR in RMS we used the RMS‐GR cell line, obtained from an embryonal rhabdomyosarcoma treated in vivo with polychemotherapy. The RMS‐GR cells showed cross‐resistance to vincristine, doxorubicin and actinomycin D, the drugs of choice in the conventional treatment of RMS. Polymerase chain reaction (PCR) analysis showed that these RMS cells overexpressed mdr1/P‐glycoprotein. The pattern of resistance and the level of P‐glycoprotein expression were similar to those found in the resistant RMS TE.32.7.DAC cell line obtained in vitro. Southern blot analysis showed that mdr1 overexpression was not due to amplification of the gene. Our results showed that the in vivo treatment of embryonal RMS may induce an MDR phenotype mediated by mdr1/P‐glycoprotein in RMS cells.
机译:横纹肌肉瘤(RMS)是儿童中最常见的软组织恶性肿瘤的经典细胞毒性治疗方法,通常伴有明显的发病率和不良反应。化学疗法可能诱导与P-糖蛋白表达相关的多药耐药性(MDR),P-糖蛋白是一种药物外排泵,可改变肿瘤细胞对药物的敏感性。为了分析RMS中的MDR,我们使用了RMS‐GR细胞系,该细胞系是通过多化学疗法体内处理的胚胎性横纹肌肉瘤获得的。 RMS-GR细胞与长春新碱,阿霉素和放线菌素D交叉耐药,后者是RMS常规治疗中的首选药物。聚合酶链反应(PCR)分析表明,这些RMS细胞过表达了mdr1 / P-糖蛋白。耐药模式和P-糖蛋白表达水平与体外获得的耐药RMS TE.32.7.DAC细胞系相似。 Southern印迹分析表明mdr1过表达不是由于基因的扩增。我们的结果表明,胚胎RMS的体内治疗可能诱导RMS细胞中由mdr1 / P-糖蛋白介导的MDR表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号